Introduced in the 1940s, Pap testing has been the single greatest contributor to the overall decline in cervical cancer. Then, the 1996 launch of the Hologic ThinPrep Pap test propelled screening success to new heights, contributing to a further 28% reduction in invasive cancers in the U.S. To date, ThinPrep has become the most widely used Pap test in the country,1 with hundreds of published, peer-reviewed studies demonstrating significant benefits over the conventional Pap smear.
Today, accurate Pap testing is even more critical in light of extended Pap testing intervals. A negative HPV test can keep patients from follow-up appointments for years, while a false negative HPV result can give cervical disease a chance to advance undetected. The ThinPrep Pap Test is the only liquid-based pap test FDA-approved/cleared for HPV, Chlamydia/Gonorrhea and Trichomonas testing out of the same vial.